Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11133221 | 0.86 | SMN1; SMN2 (0.46) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL11133219 | 0.86 | SMN1; SMN2 (0.46) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL14358816 | 0.85 | KEAP1 (0.58) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL14358814 | 0.85 | KEAP1 (0.58) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL17404864 | 0.81 | PGR (0.39) | ALDH1A1SMN1; SMN2MAPTLMNACA12 | |
| SCHEMBL15836266 | 0.79 | KEAP1 (0.52) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3554742 | 0.79 | KEAP1 (0.52) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL15218448 | 0.78 | KEAP1 (0.67) | NR3C2ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL27587461 | 0.78 | CA12 (0.53) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL8017825 | 0.77 | KEAP1 (0.54) | NR3C2ALDH1A1SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101628-B2 | Methods and composition of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | NR3C2 2799/4885ALDH1A1 3165/4885SMN1; SMN2 3111/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | NR3C2 2628/4885ALDH1A1 2855/4885SMN1; SMN2 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.